Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | NEPAFOX: adjuvant gemcitabine vs. FOLFIRINOX in resectable pancreatic cancer

Thorsten Goetze • 22 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine
NEPAFOX

Thorsten Goetze, MD, University Cancer Center Frankfurt, Frankfurt, Germany, discusses results from the NEPAFOX trial (NCT02172976), a randomized multicenter Phase II/III study investigating adjuvant gemcitabine versus neoadjuvant/adjuvant FOLFIRINOX in resectable pancreatic cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thorsten Goetze

4:59
Phase I INSIGHT platform trial: eftilagimod alpha with avelumab in advanced solid tumors
Thorsten Goetze • 26 May 2021
1:22
PREVENT: preventive HIPEC in combination with perioperative FLOT for gastric cancer
Thorsten Goetze • 26 May 2021
1:17
Future directions in gastrointestinal cancer
Thorsten Goetze • 26 May 2021
5:13
Gallbladder & bile duct cancer at ASCO GI: GAIN and other highlights
Thorsten Goetze • 22 Jan 2021

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals